Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
32 hedge funds and large institutions have $46.9M invested in Orchard Therapeutics plc American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 4 closing their positions.
629% more call options, than puts
Call options by funds: $153K | Put options by funds: $21K
79% more capital invested
Capital invested by funds: $26.2M → $46.9M (+$20.7M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
3% less funds holding
Funds holding: 33 → 32 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$62.6M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.96M |
| 3 |
Mariner
Overland Park,
Kansas
|
+$205K |
| 4 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$76.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$72.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$1.84M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$164K |
| 3 |
Goldman Sachs
New York
|
-$148K |
| 4 |
Morgan Stanley
New York
|
-$76.9K |
| 5 |
JP Morgan Chase
New York
|
-$65.1K |
ORTX Hedge Fund Activity: Q3 2023 in Review
32 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q3 2023, worth a combined $46.9M — up 79% from $26.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ORTX and 3 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.
The largest buyer was CHI Advisors, adding an estimated $62.6M. The largest seller was Temasek Holdings, exiting entirely with an estimated $1.84M sold.
- 32 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q3 2023, down from 33 in Q2 2023.
- Funds reported $46.9M of Orchard Therapeutics plc American Depositary Shares stock for Q3 2023, up 79% quarter-over-quarter.
- 3 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q3 2023 was CHI Advisors, an estimated $62.6M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q3 2023 was Temasek Holdings, an estimated $1.84M sold.
Based on aggregated 13F filings for Q3 2023.